Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Morvan Syndrome: Clinical and Serological Observations in 29 Cases
Ann Neurol 72:241-255, Irani, S.R.,et al, 2012
Autoimmune Limbic Encephalitis with GAD Antibodies
The Neurohospitalist 1:178-181, Finelli, P.F., 2011
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Voltage-gated Potassium Channel-associated Limbic Encepahlitis in the West of Scotland:Case Reports and Literature Review
Scott Med J 54:27-31, Reid,J.M.,et al, 2009
Idiopathic Transverse Myelitis. Corticosteroids, Plasma Exchange, or Cyclophosphamide
Neurol 68:1614-1617, Greenberg,B.M.,et al, 2007
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Clinicopath Conf
Hodgkin's Disease, Paraneoplastic Cerebellar Degeneration, Case 21-1997, NEJM 337:115-12297., , 1997
Progressive Encephalomyelitis with Rigidity Responsive to Plasmapheresis and Immunosuppression
Ann Neurol 40:451-453, Fogan,L., 1996
Successful Treatment of Neuropathies in Patients with Diabetes Mellitus
Arch Neurol 52:1053-1061, Krendel,D.A.,et al, 1995
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Intravascular Malignant Lymphomatosis:Amelioration of Neurological Symptoms with Plasmapheresis
Ann Neurol 35:357-359, Harris,C.P.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Plasmapheresis and Antineoplastic Treatment in CNS paraneoplastic Syndromes with Antineuronal Autoantibodies
Neurol 42:536-540, Graus,F.,et al, 1992
The Canadian Coop Trial of Cyclophosphamide and Plasma Exchange in Progr MS
The Canadian Coop MS Study Group, Lancet 337:441-4461991., , 1991
Plasma Exchange in Chronic Progressive Multiple Sclerosis:A Long-Term Study
Neurol 41:409-414, Khatri,B.O.,et al, 1991
Angiofollicular Lymph Node Hyperplasia & Peripheral Neuropathy, Case Report & Literature Review
Arch Int Med 151:789-790, Scherokman,B.,et al, 1991
The Use of Immunosuppressive Agents in the Treatment of Multiple Sclerosis:A Critical Review
Neurol 41:980-985, Goodin,D.S., 1991
Autoimmune Aetiology for Acquired Neuromyotonia (Isaacs'Syndrome)
Lancet 338:75-77, Sinha,S.,et al, 1991
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Autoantibody Synthesis in the Central Nervous System of Patients with Paraneoplastic Syndromes
Neurol 40:1085-1091, Furneaux,H.F.,et al, 1990
Double-Blind Study of True vs. Sham Plasma Exchange in Patients Treated with Immunosuppression for Acute Attacks of MS
Neurol 39:1143-1149, Weiner,H.L.,et al, 1989
Plasmapheresis in the Treatment of Stiff-Man Syndrome
NEJM 320:1499, Vicari,A.M.,et al, 1989
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
Plasma Exchange & Immunosuppressive Drug Treatment in the Lambert-Eaton Myasthenic Syndrome
Neurol 34:480-485, Newsom-Davis,J.,et al, 1984
Plasmapheresis & Immunosuppressive Drug Therapy in the Eaton-Lambert Syndrome
Ann Neurol 11:570-575, Da,P.C.,et al, 1982
Plasmapheresis in Idiopathic Inflammatory Myopathy Experience With 35 Patients
Arch Neurol 38:544-552, Dau,P.C., 1981
Controversies About the Treatment of Myasthenia Gravis
JNNP 43:644-659, Rowland,L.P., 1980
Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978
Plasmapheresis & Immunosuppressive Drug Therapy in Myasthenia Gravis
NEJM 297:1134, Dau,P.C.,et al, 1977
Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses
Ann Neurol 79:206-216,204, Kleiter, I.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Transverse Myelitis
NEJM 363:564-572, Frohman,E.M. &Wingerchuk,D.M., 2010
Clincopath Conference, Thrombotic Thrombocyclopenic Purpura in Patient with Lupus Nephritis
NEJM 363:2352-2361, Case 37-2010, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Pathophysiology of Thrombotic Thrombocytopenic Purpura
Int J Hematol 91:1-30, Tsai, H.M., 2010
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009